Compare ArcelorMittal SA (MT) vs Tango Therapeutics Inc. (TNGX) Price & Performance

ArcelorMittal (MT) trades at $62.49, down 0.73% with bearish technical signals despite recent earnings beats. The stock shows mixed fundamentals with declining revenue from $79.8B in 2022 to $61.4B in 2025, though net income improved to $3.2B. Recent Ukraine plant impairments and missile strikes create operational headwinds, while analyst consensus remains positive with a $74.33 price target representing 19% upside potential.

MT presents a value opportunity with attractive valuation multiples (P/S 0.77, P/B 0.87) and strong cash flow generation, but faces significant geopolitical risks and declining revenue trends. The company's strategic shift toward regional operations and shareholder returns supports long-term potential, though near-term volatility from European demand fluctuations and Ukraine impairments requires careful risk management.

TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.

Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.